TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical ...

Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nations As previously ...

Friday, PaxMedica Inc (NASDAQ:PXMD) completed the execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This ...

Skin Reactions Almost all antiparasitic agents may lead to allergic skin reactions: suramin-induced urticarial rash is frequent (90%) but fatal hypersensitivity reactions are very rare (1 in 20,000).

The request seeks emergency access to the Company’s recently completed registration batches of PAX-101 (IV suramin) to address the critical shortage of medications required to combat the life ...

Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nations As previously ...

In July 2023, PaxMedica released topline data from PAX-HAT-301 Retrospective Analysis of Suramin Treatment for Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (S1 TBR HAT).

PaxMedica (NASDAQ: PXMD) , a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immedia ...